Trimetazidine Therapy in Hypertrophic Cardiomyopathy
Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Hypertrophic cardiomyopathy (HCM) is a common inherited heart condition that causes
breathlessness, chest pain and fatigue. There are few treatments available. The investigators
have recently shown that a drug called perhexiline reduced symptoms and improved exercise
capacity in patients with HCM. This change appears to be driven by alterations in myocardial
energy metabolism. The aim of this trial is to test a similar drug, trimetazidine, in a group
of symptomatic patients with non-obstructive HCM.
HYPOTHESIS: trimetazidine will improve symptoms, peak oxygen consumption, cardiac function
and arrhythmia burden in medically refractory symptomatic patients with non-obstructive HCM.